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Abstract Hypertension is a major risk factor for many common chronic diseases, such as heart failure, myocardial infarction,
stroke, vascular dementia, and chronic kidney disease. Pathophysiological mechanisms contributing to the develop-
ment of hypertension include increased vascular resistance, determined in large part by reduced vascular diameter
due to increased vascular contraction and arterial remodelling. These processes are regulated by complex-
interacting systems such as the renin-angiotensin-aldosterone system, sympathetic nervous system, immune activa-
tion, and oxidative stress, which influence vascular smooth muscle function. Vascular smooth muscle cells are highly
plastic and in pathological conditions undergo phenotypic changes from a contractile to a proliferative state.
Vascular smooth muscle contraction is triggered by an increase in intracellular free calcium concentration ([Ca2þ]i),
promoting actin–myosin cross-bridge formation. Growing evidence indicates that contraction is also regulated by
calcium-independent mechanisms involving RhoA-Rho kinase, protein Kinase C and mitogen-activated protein kin-
ase signalling, reactive oxygen species, and reorganization of the actin cytoskeleton. Activation of immune/inflamma-
tory pathways and non-coding RNAs are also emerging as important regulators of vascular function. Vascular
smooth muscle cell [Ca2þ]i not only determines the contractile state but also influences activity of many calcium-
dependent transcription factors and proteins thereby impacting the cellular phenotype and function. Perturbations
in vascular smooth muscle cell signalling and altered function influence vascular reactivity and tone, important deter-
minants of vascular resistance and blood pressure. Here, we discuss mechanisms regulating vascular reactivity and
contraction in physiological and pathophysiological conditions and highlight some new advances in the field, focusing
specifically on hypertension.
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This article is part of the Spotlight Issue on Novel concepts for the role of smooth muscle cells in vascular disease.
1. Introduction
Hypertension is associated with vascular changes characterized by endo-
thelial dysfunction, increased vascular contraction, and arterial remodel-
ling.1–3 Vascular smooth muscle cells, which constitute the bulk of the
vascular wall, are critically involved in these processes through their
highly plastic and dynamic features and ability to undergo phenotypic dif-
ferentiation.1–3 Pro-hypertensive stimuli, such as activation of the renin-
angiotensin-aldosterone system (RAAS), oxidative stress, activation of
the sympathetic nervous system, haemodynamic changes, and mechani-
cal forces stimulate vascular smooth muscle cell signalling, which pro-
motes vasoconstriction, vascular hypertrophy, fibrosis, inflammation,
and calcification, processes that underlie vascular functional, structural,
and mechanical changes in hypertension.4,5
The arterial system comprises large conduit vessels, medium sized
arteries, small arteries, arterioles, and capillaries. Small resistance arteries
(lumen diameter < 300lm) are responsible for regional distribution of
vascular tone and blood flow and play an important role in the regulation
of blood pressure, through effects on vascular resistance.6 Three funda-
mental parameters determine resistance to blood flow including vessel
diameter (radius), arterial length, and blood viscosity. Of these, vessel
diameter is the most important because it can change rapidly due to con-
traction and dilation of vascular smooth muscle.6 Based on Poiseuille’s
Law, vessel resistance is inversely proportional to the radius (lumen
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diameter) to the fourth power (r4). Therefore, small changes in lumen
diameter have major impact on vascular resistance.7 The lumen diameter
of resistance arteries is a function of vasomotor tone (vasoconstriction/
vasodilation) and the structural and mechanical properties of the vessel.
Vasomotor control underlies acute rapid adaptation of vessel diameter
due mainly to vasoconstriction exerted by the active contraction of vas-
cular smooth muscle cells, while changes in vascular structure represent
a dynamic process in response to chronic haemodynamic changes.8
Initially structural changes are adaptive but in chronic pathological condi-
tions become maladaptive leading to vascular remodelling and rigid, stiff,
and poorly compliant vessels, typically observed in chronic hyper-
tension.9,10 Endothelial stiffening decreases nitric oxide generation lead-
ing to smooth muscle cell contraction and vasoconstriction and may
precede hypertension. Arterial stiffness is strongly associated with high
blood pressure and is an independent predictor of cardiovascular
disease.11,12
At the molecular and cellular levels vascular hyperreactivity, remodel-
ling, and stiffening involve changes in cytoskeletal organization, cell-to-cell
connections, cell growth, calcification, inflammation, and rearrangement
of vascular smooth muscle cells.13,14 At the extracellular level, remodel-
ling is influenced by fibrosis, changes in matrix protein composition and
reorganization of proteoglycans, collagens, and fibronectin, which provide
tensile strength, and elastin, responsible for vascular elasticity. Activation
of adipocytes in perivascular adipose tissue, secrete vasoactive adipokines
that also influence vascular reactivity and contractility.15,16
Acute regulation of vascular diameter and consequently vascular
resistance depends on the activation status of the contractile machinery
involving actin: myosin interaction in vascular smooth muscle cells.17
Changes in [Ca2þ]i, ion fluxes, and membrane potential lead to calcium–
calmodulin-mediated phosphorylation of the regulatory myosin light
chains (MLCs) and actin–myosin cross-bridge cycling with consequent
rapid vasoconstriction.18 Calcium-independent mechanisms associated
with altered calcium sensitization and actin filament remodelling and
increased bioavailability of reactive oxygen species (ROS) (oxidative
stress), also modulate vascular contraction.19
In the present review, we discuss mechanisms regulating vascular
reactivity and contraction in physiological and pathophysiological condi-
tions, with a particular focus on hypertension. The role of vascular
smooth muscle function in vascular remodelling, inflammation, and calci-
fication and the importance of other vascular cell types in vascular health
and disease are discussed elsewhere in the current issue of the journal.
2. The vascular media
The arterial wall is composed of three anatomical layers, a single layer of
endothelial cells, the vascular media comprising multiple layers of vascu-
lar smooth muscle cells, and the adventitia, containing fibroblasts, adipo-
cytes, connective tissue, and extracellular matrix.20–23 Endothelial cells
secrete vasoactive agents and ROS that modulate the vessel diameter by
influencing vascular smooth muscle cell function.20 The muscular media
of vessels is innervated by the autonomic nervous system and its con-
tractile state is regulated by hormones, vasoactive peptides, and ROS.
Vascular smooth muscle cells possess a complex cytoskeletal skeleton,
structural, and functional contractile proteins and associated regulatory
molecules. Individual vascular smooth muscle cells connect to neigh-
bouring cells through gap junctions, such as connexins, which control
the synchronization in ion concentration and membrane potential
between neighbouring cells.22,23
Although smooth muscle contraction can be tonic (sustained) or pha-
sic, tonic contraction is essential for maintenance of vascular tone and
regulation of blood flow. In resistance arteries vessels contract in
response to increasing pressure in the physiological range (70–
100mmHg). With increased blood pressure, this myogenic response is
impaired and basal vascular tone and contractility are increased.24
Clinically, non-invasive approaches (vascular ultrasound, pulse wave anal-
ysis, and peripheral arterial tone) to study endothelial function and vas-
cular tone in humans have demonstrated that patients with hypertension
exhibit impaired endothelium-dependent vasodilation, enhanced vascu-
lar reactivity, and increased contractility.25
3. The plastic nature of vascular
smooth muscle cells
Vascular smooth muscle cells are specialized cells that are highly plastic
and multifunctional. Physiologically vascular smooth muscle cells are qui-
escent and exhibit low levels of growth. Normally, they express genes
and proteins important for contraction/dilation, which allows them to
control systemic and local pressure through the regulation of vascular
tone.26 However, under stressed or pathological conditions, highly dif-
ferentiated contractile cells re-enter the cell cycle and become dediffer-
entiated, assuming a proliferative/migratory phenotype. Although
differentiated cells express specific contractile and cytoskeletal proteins
[e.g. smooth muscle cell a actin (a-SMA), smooth muscle myosin heavy
chain (SM-MHC), calponin, caldesmon, and sm22-a], dedifferentiated
cells express low levels of contractile markers and high levels of signalling
molecules associated with cell growth, migration, fibrosis, and inflamma-
tion [e.g. cell cycle regulators (cyclins), mitogen-activated protein kinases
(MAPKs), pro-inflammatory transcription factors, and matrix
metalloproteinases].27
3.1 Vascular smooth muscle
dedifferentiation in hypertension
In hypertension and other pathological conditions associated with vascu-
lar injury, the phenotypic switch contributes to vascular dysfunction and
arterial remodelling. In the early stages of hypertension and during vascu-
lar repair, the cell cycle is tightly regulated contributing to controlled vas-
cular smooth muscle cell proliferation important in the ‘adaptive’ phase
of remodelling. However when the cell cycle is unchecked and prolifera-
tion is uncontrolled, dedifferentiated smooth muscle cells accumulate in
the vascular wall leading to media thickening, neointimal hyperplasia, and
vascular stiffness, features found in hypertension, atherosclerosis, and
pulmonary artery hypertension.28 Studies using cell-tracking approaches
in in vivo models, demonstrated that>80% of vascular smooth muscle
cells in sites of arterial injury or vascular remodelling exhibit features of
dedifferentiation.29
3.2 Molecular mechansims of vascular
smooth muscle cell dedifferentiation in
hypertension
Molecular mechanisms underlying the cellular phenotypic switch in
hypertension are complex and multifactorial. Vasoactive stimuli
[Angiotensin II (Ang II), norepinephrine, and endothelin-1 (ET-1)],
growth factors [Insulin-like growth factor 1 (IGF-1), epidermal growth
factor (EGF), platelet-derived growth factor (PDGF)], mechanical forces
(stretch), and physical factors (shear stress, pressure) are important.30,31
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These processes induce changes in expression and function of genes that
control cell membrane receptors, growth signalling pathways, extracellu-
lar matrix components, transcription factors, ion channels, and trans-
porters, important in vascular hypertrophy in hypertension.31–33
3.3 The non-coding genome and
dedifferentiation of vascular smooth
muscle cells in hypertension
Recent evidence indicates that the phenotypic switch of smooth muscle
cells involves the non-coding genome. Non-coding RNAs (ncRNAs),
which are classified based on their size: small ncRNAs (<200 nucleoti-
des) and long ncRNAs (lncRNA) (>200 nucleotides), regulate gene
expression at multiple levels including transcription, RNA processing,
and translation.26,34 Most ncRNAs do not have protein-coding abilities
but they guide DNA synthesis or genome rearrangement and as such
have major impact on the regulation of the genome.
Many classes of small ncRNAs have been identified, of which miRNAs
are particularly important in the phenotypic regulation of smooth muscle
cells. Mature miRNA derives from precursor miRNA through cleavage
by the enzyme Dicer. Evidence supporting a pathophysiological role for
miRNA in smooth muscle cell differentiation and proliferation derives
from in vivo studies in conditional knockout mice, where smooth muscle
cell-specific knockout of Dicer was associated with dilated, thin-walled
arteries, reduced vascular smooth muscle cell proliferation, decreased
expression of contractile genes, and decreased blood pressure.34,35
Similar features were observed in mice deficient in smooth muscle cell
miR-143/145 cluster.36 Other miRNAs associated with vascular smooth
muscle cell differentiation include miR-21, miR-22, miR-26a, miR-34a,
miR-146a, and miR-221/222.26,34–36
Although the list of miRNAs involved in vascular smooth muscle cell
differentiation is growing, there is a paucity of information on vascular
cell lncRNAs. LncRNA regulate gene expression by stimulating or
repressing gene transcription, translation, and signalling. They also regu-
late the structure and function of chromosomes. Multiple lncRNAs,
including H19, ANRIL, lncRNA-p21, lncRNA-362, and GAS5, have been
associated with vascular smooth muscle cell differentiation/proliferation
and various vascular pathologies.37 Most lncRNA are widely expressed,
however, smooth muscle and endothelial cell enriched migration/
differentiation-associated lncRNA (SENCR) seems to be specifically
expressed in smooth muscle cells and endothelial cells.35 Numerous
Ang II-regulated lncRNAs have been identified in vascular remodelling in
experimental hypertension.38 In particular, lncRNA-GAS5 (growth
arrest-specific 5) has been identified as a regulator of hypertension-
induced vascular remodelling, which when knocked down causes
hypertension.39
4. Vascular contraction and
hypertension
Dynamic changes in vascular diameter depend in large part on the con-
tractile activation and inactivation (phosphorylation/dephosphorylation)
of contractile proteins in vascular smooth muscle cells. The contractile
machinery of vascular smooth muscle includes actin and myosin and a
highly organized cytoskeleton.
4.1 A primer in vascular smooth muscle
contraction: Ca21-dependent mechanisms
The key event in vascular smooth muscle excitation-contraction cou-
pling is an increase in [Ca2þ]i in response to mechanical, humoral, or
neural stimuli40,41 (Figure 1). [Ca2þ]i and calcium signalling control the
key functions of vascular smooth muscle cells and are finely tuned by
plasma membrane calcium-permeable channels, exchangers, and trans-
porters and by intracellular sources, including the sarcoplasmic reticu-
lum, mitochondria, and calcium-binding proteins. The extracellular
concentration of calcium is 2–4mM with a basal [Ca2þ]i of 90–110
nM.40–42 In hypertension, these processes are altered leading to
increased [Ca2þ]i and a hypercontractile state and vascular remodelling.
Stimulation of vascular smooth muscle cells by pro-hypertensive fac-
tors such as neurohumoral stimuli (acetylcholine, norepinephrine) and
vasoactive peptides (Ang II, ET-1), induces activation of receptors
coupled to Phospholipase C (PLC), leading to generation of the second
messengers inositol trisphosphate (IP3) and diacylglycerol (DAG).
31,40–42
Circulating non-cellular factors such as cytokines, diffusible ROS (nitric
oxide and hydrogen peroxide), and miRNAs and cellular-derived factors
such as microparticles and endothelial progenitor cells also stimulate
membrane receptors or cross the plasma membrane to regulate path-
ways that control [Ca2þ]i.
43–45 Moreover, endothelium-secreted vaso-
constrictors regulate vascular contraction. Endothelial-derived ET-1 and
prostanoids activate vascular smooth muscle cell receptors leading to
activation of pro-contractile signalling.46
PLC-induced IP3 production stimulates intracellular calcium release
from the sarcoplasmic reticulum and DAG causes activation of protein
kinase C (PKC). In addition, numerous calcium channels, such as voltage-
operated (VOC), receptor-operated channels (ROC), store-operated
channels (SOC), transient receptor potential cation (TRP) channels and
Ca2þ-permeable non-selective cation channels are activated, promoting
calcium influx and increased [Ca2þ]i.
47–51 Calcium diffuses to the contrac-
tile machinery and binds to calmodulin. The calcium–calmodulin complex
induces a conformational change in MLC kinase (MLCK) converting it
from an inactive to an active state.40–43 Activated MLCK induces phos-
phorylation of MLC20, stimulates myosin–actin interaction, which gener-
ates force and shortening and consequent vascular contraction.
4.2 Calcium-dependent mechanisms of
vascular smooth muscle cell contraction
in hypertension
In hypertension, many of the mechanisms regulating intracellular calcium
homeostasis are perturbed, with experimental models and hypertensive
patients demonstrating abnormal vascular calcium handling and high
[Ca2þ]i. Increased calcium influx, augmented sarcoplasmic reticular cal-
cium release and decreased sarcoplasmic reticular calcium reuptake,
activation of the PLC-DAG-IP3 pathway, increased calcium signalling,
vascular hyperreactivity, and exaggerated contractile responses to vaso-
active agonists have been demonstrated in genetic [spontaneously
hypertensive rats (SHRs), stroke-prone SHR], experimental (deoxycor-
ticosterone acetate (DOCA)-salt, Ang II-infused, L-NAME-induced), and
human hypertension.47–54 Processes triggering these events in hyperten-
sion likely involve activation of the sympathetic nervous system and up-
regulation of the RAAS.
The importance of calcium channels in abnormal calcium handling in
hypertension is evidenced by the effective antihypertensive actions of L-
type calcium channel blockers, which target L-type CaV1.2 calcium
channels.55,56 In experimental and clinical hypertension, activation of L-
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greater in hypertensive compared with normotensive individuals.55,56
Processes underlying this include increased expression and phosphoryla-
tion of subunits of L-type calcium channels.55 Other mechanisms involv-
ing regulatory factors have also been identified. In particular, recent
studies demonstrated that the splicing factor Rbfox2 plays a regulatory
role in CaV1.2 calcium channels and calcium influx in vascular smooth
muscle cell contraction. In hypertension, aberrant splicing by dysregu-
lated Rbfox2 induces enhanced activity of CaV1.2 calcium channels lead-
ing to increased vascular myogenic tone.57
ROCs, TRP channels (TRPC3, TRPC6, and TRPC7), and the Naþ/
Ca2þ exchanger (NCX) have also been shown to play a role in altered
calcium handling and vascular dysfunction in hypertension.50 Moreover,
processes that stimulate store-operated calcium entry (SOCE) may be
important. SOCE, a mechanism whereby reduced sarcoplasmic reticular
calcium stores stimulate calcium influx, is influenced by stromal interac-
tion molecule 1 (STIM1) and Orai1 (pore subunit of calcium release-
activated calcium channels). In hypertension, increased expression of
vascular STIM1/Orai1 is associated with augmented aortic contraction,
especially in males.50,58
Figure 1 Calcium-dependent regulation of vascular smooth muscle cell (VSMC) contraction. Vasoconstrictors induce VSMC contraction by increasing
the intracellular levels of Ca2þ. Vasoactive peptides, such as Ang II, bind to G protein-coupled receptors (GPCRs) activating PLC leading to (i) production of
IP3 and (ii) formation of DAG. IP3 binds to the IP receptor Ca
2þ channel (InsP3R) and induces Ca2þ release from the sarcoplasmic reticulum (SR). DAG
causes activation of PKC, which influences Ca2þ channels, such as store-operated Ca2þ channel (SOC), second messenger-operated Ca2þ channel
(SMOC), receptor-operated Ca2þ channel (ROC), voltage-gated Ca2þ channel (VOC), and the Naþ–Ca2þ exchanger (NCX). PKC also stimulates activity
of the ryanodine Ca2þ channel (RyR) inducing release of Ca2þ from the SR. MLCP activity is reduced by CPI-17 phosphorylation. Ca2þ binds to calmodulin
and activates the MLCK, leading to MLC20 phosphorylation at Ser19, actin polymerization, and vascular contraction.
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In hypertension, vascular smooth muscle calcium homeostasis is also
modulated by activation of signalling pathway not typically associated
with contration, such as MAPKs, tyrosine kinases, transcription factors,
and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(Noxs).59–63 We showed that c-Src is a point of cross-talk between cal-
cium- and oxidation/reduction (redox)-signalling in vascular cells and
that in human hypertension, up-regulation of this system contributes to
increased vascular [Ca2þ]i and contraction.
64 Redox-regulated calcium-
sensitive transcription factors, including serum response factor (SRF),
nuclear factor of activated T-cells (NFAT), and cyclic adenosine mono-
phosphate (cAMP) responsive element-binding protein, promote
expression of genes encoding contractile proteins, further influencing
vascular contractility in hypertension.50
Involvement of immune and inflammatory systems has also been
shown to influence vascular calcium homeostasis in hypertension and
target organ damage in hypertension. Activated immune cells migrate
into target organs, including the vasculature, and factors released by
these cells, including ROS, metalloproteinases, cytokines, and chemo-
kines promote dysfunction and cause damage.65 In vessels, these factors
enhance constriction, remodelling, and rarefaction. Vascular toll-like
receptors (TLRs) and damage-associated molecular patterns (DAMPs)
have also been shown to influence vascular reactivity in hypertension.
TLR4 is up-regulated in resistance arteries of SHR and contributes to
hypercontractile responses through DAMP and cyclooxygenase-
dependent pathways.66 In hypertension, increased DAMP-TLR activation
may influence vascular reactivity as well as elicit a vascular inflammatory
response, also important in the pathophysiology of hypertension.
Involvement of immune cells in the perivascular adventitial and adipose
tissue has also been implicated in hypertension-associated vascular
dysfunction.67
4.3 Calcium-independent mechanisms of
vascular smooth muscle cell contraction in
hypertension: calcium sensitization
In addition to calcium-dependent mechanisms, calcium-independent
processes regulate vascular smooth muscle contraction, by influencing
the sensitivity of MLC to calcium. The calcium sensitization process
maintains force generation following dissipation of the initial calcium sig-
nal. Twomajor signalling pathways have been implicated in calcium sensi-
tization, including the DAG-PLC-PKC pathway and the RhoA-Rho
kinase (ROCK) pathway67,68 (Figure 2). Other kinases also play a role
including integrin-linked kinase (ILK), p21-activated protein kinase and
zipper-interacting protein kinase (ZIPK).69,70 The calcium sensitization
mechanism regulates the phosphorylation state of MLC20 independently
of calcium–calmodulin–MLCK signalling.
Hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2) by PLC
produces IP3 and DAG. IP3 stimulates release of calcium from the sarco-
plasmic reticulum, while DAG acts as a second messenger inducing acti-
vation of PKC and C-kinase potentiated protein Phosphatase 1 inhibitor,
molecular mass 17 kDa (CPI-17). PKCs are classified in three major
groups; conventional or classic PKCs, novel PKCs, and atypical PKCs.
Vascular smooth muscle cells variably express multiple isoforms,
although the classic isoforms, a, b, and c appear to be most abundant.
Activated PKC induces phosphorylation of downstream targets including
ion channels, transporters, and nuclear protein.71 It also phosphorylates
CPI-17, a smooth muscle-specific inhibitor of MLC phosphatase (MLCP),
which binds to its catalytic domain, inhibiting phosphatase activity, facili-
tating persistent contraction. a-PKC also induces phosphorylation
of actin-binding proteins, such as calponin and calmodulin, which pro-
mote actin–myosin interaction and vascular smooth muscle cell
contraction.72
Increased PKC activity, associated with vascular hypercontractility, has
been demonstrated in experimental and clinical hypertension. Agonist-
stimulated vasoconstriction is more potently inhibited by PKC inhibitors
in aorta from SHR vs. control Wistar Kyoto rats.73 Moreover, hindlimb
perfusion of a phorbol ester that activates PKC, caused prolonged vaso-
constriction, and increased perfusion pressure in SHR compared with
normotensive WKY, effects that were blocked by PKC inhibitors.74
Human vascular smooth muscle cells from hypertensive patients exhibit
increased Ang II-induced proliferation and contraction through proc-
esses that involve Phospholipase D and PKC.75 Several PKC inhibitors
have been developed, including non-specific staurosporine and cheler-
ythrine, which reduce contraction in hypertension. Isoform-specific PKC
inhibitors, such as ruboxistaurin have been tested in clinical trials for dia-
betic retinopathy76 and may have potential in the treatment of other vas-
cular diseases.
The other system that sensitizes myosin to calcium involves ROCKs
(ROCK1, ROCK2), which are serine/threonine kinases and downstream
effectors of the small GTPase RhoA.77,78 RhoA, a member of the Rho
family of small GTPase-binding proteins, is abundantly expressed in vas-
cular smooth muscle cells and is rapidly activated by vasoconstrictors,
such as Ang II. ROCK influences calcium sensitization through two main
mechanisms. First, it stimulates phosphorylation of myosin phosphatase
target subunit 1 (MYPT1) at T695 or T853. Secondly, it phosphorylates
ZIPK (also known as DAPK3), which stimulates phosphorylation of
MYPT1 at T696 and T18/S19.79,80 MYPT1 phosphorylation in turn inter-
feres with binding of MLCP to MLC, and accordingly reduces phospha-
tase activity leading to sustained contraction. In addition to MYPT1,
ROCK phosphorylates CPI-17.81 Hyperactivation of the RhoA-ROCK
leads to decreased MLCP activation and consequent sustained vasocon-
striction and blood pressure elevation. ROCK-dependent calcium sensi-
tization is particularly important in the acute phase of vasoconstriction,
as evidenced by studies demonstrating that blockade of this pathway
reduces the initial vasoconstrictor action of mechanical, humoral, and
neural stimuli.82
Experimental models of hypertension exhibit increased vascular
RhoA/ROCK activation,76,83–86 processes that are augmented with high
salt diet.83 A number of mechanisms have been implicated in ROCK
hyperactivation in hypertension, including dysregulation of Rho guanine
nucleotide exchange factors (Rho-GEFs).84 In experimental hyperten-
sion, activation of ROCK signalling generates a negative feedback loop
on the expression of vascular RhoA-GEFs, which influences ROCK-
dependent contraction or remodelling in vessels under pathophysiologi-
cal conditions, including hypertension.85–88 In clinical studies, mononu-
clear cell p63RhoGEF gene and protein expression and MYPT1
phosphorylation were increased in patients with essential hyper-
tension.88 ROCK2 also plays an important role in Ang II-induced hyper-
tension and cardiac hypertrophy, through processes that involve formin
Homology 2 domain containing 3 (FHOD3), crucial in regulating myofi-
brillogenesis in cardiomyocytes.87 In human vascular smooth muscle
cells, Ang II activates ROCK-mediated contractile signalling through the
RhoA exchange factor Arhgef1.88 In addition to modulating vascular con-
traction in hypertension, ROCK activation is associated with increased
vascular stiffness through processes that increase SRF/myocardin
signalling.89
Pharmacological inhibition of ROCK with fasudil or Y27632 sup-
presses acute pressor responses of Ang II but does not reduce blood
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pressure chronically, supporting the role of RhoA/ROCK in acute vaso-
constriction, rather than in mechanisms associated with adaptive vascu-
lar remodelling in hypertension that occur chronically with Ang II
infusion.90–93 Clinical studies have demonstrated beneficial effects of
ROCK inhibitors. Fasudil has been used clinically and prevents vaso-
spasm associated with subarachnoid haemorrhage, acute ischaemic
stroke, angina, coronary artery spasm, atherosclerosis, and in the regula-
tion of vascular tone in hypertensive renal transplant recipients.91–96
Increasing evidence indicates a pathophysiological role for ROCK in pul-
monary arterial hypertension, with clinical studies suggesting ROCK
inhibitors as potential therapeutic agents.96 Use of ROCK inhibitors in
human essential hypertension is not yet approved but may be an inter-
esting strategy.
5. Reversal of vascular smooth
muscle contraction—importance of
vascular relaxation
Vascular smooth muscle relaxation occurs as a result of decreased
[Ca2þ]i due to inactivation of L-type calcium channels with reduced cal-
cium influx, increased plasmalemmal Ca2þATPase and activation of the
sodium–calcium exchanger with increased calcium efflux and activation
of sarcoplasmic/endoplasmic reticulum Ca2þATPase (SERCA), which
stimulates reuptake of calcium into the sarcoplasmic reticulum. As cal-
cium dissociates from calmodulin, MLCK becomes inactivated and
MLC20 is dephosphorylated by the serine/threonine phosphatase
Figure 2 ROCK-induced contraction of VSMCs. Vasoactive agents bind to their respective GPCRs leading to release of RhoA from a guanine nucleotide
dissociation inhibitor (GDI). RhoA translocates to the membrane. Mechanisms involving RhoA activation also involve transactivation of receptor tyrosine
kinases (RTKs). GEFs promote exchange of Guanosine diphosphate (GDP) to Guanosine triphosphate (GTP), activating the RhoA-ROCK pathway.
Activated ROCK renders MLCP inactive by phosphorylation of CPI-17 and/or zipper-interacting protein (ZIPK), facilitating MLC20 phosphorylation and vas-
cular contraction. Increased Ca2þmay directly activate ROCK through phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)-dependent pathways.
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MLCP.97,98 The overall magnitude of MLC20 phosphorylation and resul-
tant vascular smooth muscle contraction are determined by the relative
activities of MLCK and MLCP. Another pathway promoting vascular
relaxation involves endothelial-derived nitric oxide that regulates cyclic
guanosine monophosphate and cAMP, which signal through protein kin-
ase G (PKG) and protein kinase A (PKA) to increase MLCP activity and
decrease calcium sensitivity of the contractile machinery.99,100
Impaired vasorelaxation, with sustained contraction and altered
MLCP activity have been demonstrated in human and experimental
hypertension.101 In smooth muscle from mice with specific knockout of
the MLCP regulatory subunit MYPT1, phosphorylation of MLC and con-
tractile force in isolated mesenteric arteries were enhanced, indicating
an important role for MLCP and its regulatory subunit MYPT1 in vascular
contraction and development of hypertension.102
6. The actin cytoskeleton and
contraction
In addition to the calcium-dependent and -independent modulation of
MLC20 phosphorylation and actin–myosin cross-bridge formation, reor-
ganization of actin filaments, intermediate filaments, and microtubules
play an important role in vascular contraction. Increased polymerization
of actin, tyrosine phosphorylation of paxillin, activation of small GTP-
binding proteins, and conformational changes in focal adhesion sites
result in stiffening and reorganization of the cytoskeleton in vascular
smooth muscle cells.103 This dynamic rearrangement of the actin cytos-
keleton is key in maintaining vascular tone and plasticity, especially
important in the regulation of vascular diameter related to pressure-
dependent myogenic tone in hypertension. Cytoskeletal remodelling
occurs over time, with actin polymerization increasing as vasoconstric-
tion persists.104 This involves cellular reorganization and formation of
new intercellular adhesions through integrins and focal adhesion mole-
cules.105,106 Prolonged vasoconstriction and associated actin polymeriza-
tion participate in the initial phases of vascular remodelling in
hypertension, processes that involve ROCK and ROS.107 Vascular
smooth muscle cell length adaptation, with reorganization of the actin
cytoskeleton also contributes to small artery eutrophic remodelling, typ-
ically observed in essential hypertension.108
7. Reactive oxygen species, calcium,
and contraction in hypertension
Similar to intracellular calcium, ROS are now considered important sec-
ond messenger molecules in vascular smooth muscle cells in that (i) they
are generated within cells in a regulated manner, (ii) they act on down-
stream signalling molecules, and (iii) their effects on protein targets
reversibly influence cellular function.109 ROS (superoxide anion and
hydrogen peroxide) and reactive nitrogen species (nitric oxide and per-
oxynitrite) are biologically important O2 derivatives that play a role in
vascular (patho)biology through their redox potential. The major enzy-
matic source of ROS in endothelial and vascular smooth muscle cells is
Nox. Seven Nox isoforms have been identified, of which Nox1, 2, 4, and
5 are expressed and functionally active in human vascular smooth muscle
cells.110–112 Noxs are activated by vasoactive agents and activation is
increased in hypertension.113,114 Superoxide is converted to the more
stable hydrogen peroxide by superoxide dismutase (SOD). Hydrogen
peroxide is further reduced to water and oxygen by catalase and
peroxidases. In endothelial cells, superoxide reacts with nitric oxide pro-
ducing peroxynitrite. An imbalance in redox state where pro-oxidants
overwhelm antioxidant capacity leads to oxidative stress, which in turn
causes vascular inflammation, fibrosis and arterial remodelling in
hypertension.115
Vascular ROS effects are mediated through redox-sensitive signalling
pathways. ROS regulate protein kinases, phosphatases, MAPKs, and tran-
scription factors and are important modulators of [Ca2þ]i, ROCK, and
the contractile machinery (Figure 3). ROS increase vascular [Ca2þ]i by
stimulating IP3-mediated calcium mobilization, by increasing cytosolic cal-
cium accumulation through SERCA inhibition, and by stimulating calcium
channels.116,117 IncreasedNox-derived ROS generation enhances calcium
signalling, up-regulates ROCK and modulates the actin cytoskeleton,
thereby promoting vascular contraction and increasing vascular tone.
Superoxide causes vasoconstriction while hydrogen peroxide induces
both vasodilation and vasoconstriction, depending on the vascular bed
and the Nox isoform involved. In cerebral arteries, coronary arteries,
and pulmonary vessels, hydrogen peroxide is a potent vasodilator,118,119
whereas in peripheral arteries and aorta it causes vasoconstriction.120,121
Hydrogen peroxide acts as an endothelium-derived hyperpolarizing fac-
tor and induces vasodilation through PKG1a-mediated pathways122,123
and inhibition of intracellular calcium mobilization, while ROS mediates
vasoconstriction by increasing [Ca2þ]i.
52
8. Oxidative stress, protein
oxidation, and vascular contraction
ROS influence pro-contractile signalling through post-translational oxi-
dative modification of proteins. Cysteine and methionine residues on
proteins are highly redox-sensitive and undergo oxidative modification
when ROS production is increased, such as in hypertension.124 Under
physiological conditions, protein oxidation is usually reversible, while in
pathological conditions associated with oxidative stress, protein oxida-
tion may be irreversible resulting in oxidative damage of proteins and
cell death. Many proteins that regulate vascular smooth muscle cell cal-
cium homeostasis, including calcium channels, SERCA, TRP channels,
and ROCK, undergo post-translational oxidative modifications.125–127 In
addition, actin and actin-binding proteins, myosin and cofilin, are directly
oxidized by ROS.128,129 Accordingly, increased vascular Nox-derived
ROS generation in hypertension causes an increase in [Ca2þ]i and cytos-
keletal rearrangement leading to altered vascular reactivity and enhanced
contraction.
9. Conclusions
Vascular smooth muscle cells are highly differentiated and normally
maintain a contractile phenotype. Vascular contraction/relaxation is
regulated by many processes that are both calcium-dependent and -
independent and involve calcium channels and signalling pathways such
as IP3-PKC-DAG and ROCK. In hypertension, these processes are dys-
regulated, and signalling pathways not typically associated with contrac-
tion, such as MAPKs, tyrosine kinases, and transcription factors are
activated. These phenomena lead to a hypercontractile state and dedif-
ferentiation of vascular smooth muscle cells to a proliferative/migratory
phenotype with consequent vascular remodelling. Emerging evidence
also implicates a role for the immune/inflammatory system and the non-
coding genome in vascular dysfunction in hypertension. Unravelling the
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.complex interactions between traditional pro-contractile calcium-regu-
lated signalling pathways and non-traditional contractile mechanisms will
provide better insights into processes underlying the vascular phenotype
in hypertension.
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